HIV CURE SYMPOSIUM

in collaboration with the 2000HIV consortium

22-25 September, Ghent, Belgium

Program


The program offers multiple perspectives on the HIV cure field, showcasing exciting recent research findings with potential for clinical translation. 

The conference sessions will present the latest research and foster discussion on:

• The establishment of the HIV reservoir

• The adaptive and innate immune responses associated with HIV control

• The molecular characteristics of the viral reservoirs 

• The development of new therapies


SUNDAY 22 SEPTEMBER 2024
OPENING HIV CURE SYMPOSIUM - KEYNOTE LECTURE
18.00-18.30Future directions for HIV Cure research
Ole Sogaard, Aarhus University, Denmark
18.30-19.002000HIV Study
Andre Van der Ven, Radboud UMC, The Netherlands
19.00-20.00Different perspectives on HIV cure trials

20.00-21.00Opening Reception

MONDAY 23 SEPTEMBER 2024
SESSION 1 – ‘VIRAL INTEGRATION’: CHROMOSOMAL ARCHITECTURE
08.30-08.55HIV targeted integration in the context of chromatin structure
Monsef Benkirane, Research Director CNRS, France
08.55-09.20Integration site selection, genomic features of integration sites and impact of viral expression
Angela Ciuffi, CHUV, Switzerland
09.20-09.45Establishment of the viral reservoir during early infection
Linos Vandekerckhove, Ghent University, Belgium
09.45-10.10Immune selection of proviral DNA by CTL responses
Brad Jones, Weill Cornell Medicine, USA
10.15-10.45Break
SESSION 2 – COMPOSITION AND EVOLUTION OF THE VIRAL RESERVOIR
10.45-11.10Composition of the reservoir in the 2000HIV study: clinical data and biomarker analysis
Mareva Delporte, Ghent University, Belgium
11.10-11.35HIV Expression in Infected T cell Clones
Mary Kearney, National Institue for Medical Research, Australia
11.35-12.00Understanding the viro-immunological mechanisms contributing to HIV control during an analytical treatment interruption
Sarah Palmer, The Westmead Institute for Medical Research, Australia
12.00-12.25HIV diversity, tropism and immunological control in the 2000HIV study
Kavita Mehta and Sofie De Braekeleer, Ghent University, Belgium
12.30-14.00Lunch
SESSION 3 – REACTIVATION OF THE VIRAL RESERVOIR
14.00-14.25Reactivation of the viral reservoir by TAT LNPs
Daniel Claiborne, The Wistar Institute, USA
14.25-14.50Role of immune homeostasis in reaching a low reservoir
Ashish Sharma, Emory University, USA
14.50-15.40Block and lock versus shock and kill
Zeger Debyser versus Carine Van Lint, Belgium
15.45-16.15Break
SESSION 4– INSPIRATIONAL SESSION
16.15-17.00Satellite session ViiV Healthcare
17.00-17.45Lessons learned from the cancer field
Rafick Sékaly, Emory University, USA
18.00-20.00Poster session and dining and wining
TUESDAY 24 SEPTEMBER 2024
SESSION 5 – CELL AND IMMUNE BASED THERAPY TO ELIMINATE THE RESERVOIR
08.30-08.55The kitchen sink study
Michael Peluso, Zuckerberg San Francisco General Hospital
University of California, United States
08.55-09.20Increasing longevity of CAR T cells after infusion
Wojciech Witkowski, Ghent University, Belgium
09.20-09.45Implementing Gene therapy studies in Africa
Cissy Kytyo, USAID, United states
09.45-10.10TBC
Christopher Peterson, Fred Hutchinson Cancer Center, United States
10.15-10.45Break
SESSION 6 – MODULATION OF INNATE IMMUNITY
10.45-11.10Immune aging
Mihai Netea, Radboud UMC, The Netherlands
11.10-11.35Integrative omics reveal the genetic and molecular landscape of immune responses and comorbidities in people living with HIV
Javier Botey, Helmholtz Centre for Infection Research, Germany
11.35-12.00Innate memory in HIV controllers
Jéssica dos Santos, Radboud UMC, The Netherlands
12.00-12.25Impact of food intake on immune system and inflammation
Quirijn de Mast, Radboud UMC, The Netherlands
12.30-14.00Lunch
SESSION 7 – MODULATION OF INNATE IMMUNITY
14.00-14.25Peristent inflammation in people treated during acute infection
Sarah Gerlo, Ghent University, Belgium
14.25-14.50Unravelling Molecular Signatures and Causal Factors underlying latent Cytomegalovirus infection among PLHIVs
Yang Li, Helmholtz Centre for Infection Research, Germany
14.50-15.15Innate immunity and comorbidities
Twan Otten, Radboud UMC, The Netherlands
15.15-15.40Microbiome and HIV
Jing Fu
15.45-16.15Break
SESSION 8– CELL AND IMMUNE BASED THERAPY TO ELIMINATE THE RESERVOIR
16.15-16.40Assessing immunogenicity barriers of the HIV-1 envelope trimer
Rogier Sanders, Amsterdam UMC, The Netherlands
16.40-17.05Beyond T-cell based therapeutic vaccines
Beatriz Mothe Pujadas, Institut de Recerca de la Sida IrsiCaixa, Badalona, Spain
17.05-17.30TBC
TBC
19.00-22.00Speakers dinner
WEDNESDAY 25 SEPTEMBER 2024
SESSION 9 – HIV PERSISTENCE IN TISSUE
08.30-08.55Towards understanding the in-situ interplay between HIV and host
Constantinos Petrovas, University Hospital of Lausanne, CHUV, Lausanne, Switzerland
08.55-09.20Translation competent virus in lymph node and gut
Marion Pardons, Ghent University, Belgium
09.20-09.45Role of tissue NK cells in HIV persistence
Maria Buzon, Vall d’Hebron Institute of Research (VHIR), Spain
09.45-10.10Polyfunctional T cell responses in nonhuman primates
Susan Pereira, Emory University, Belgium
10.15-10.45Break
SESSION 10 – KEYNOTES AND FUTURE PERSPECTIVES
10.45-11.25TBC
TBC
11.25-12.05Role of ILCs in HIV persistence
TBC
12.05-12.25Future perspectives towards cure
Jan van Lunzen, Radboud UMC, The Netherlands
12.25-12.35Closing remarks